论文部分内容阅读
目的 检测胰腺癌组织中GST-π耐药基因的表达及其临床意义。方法 采用S-P免疫组织化学方法对150例异常和正常胰腺石蜡切片组织标本（包括原发性胰腺癌97例,胰腺炎32例和正常胰腺组织21例）进行GST-π耐药基因蛋白表达检测。结果GST-π耐药基因在胰腺癌。胰腺炎和正常胰腺组织中阳性率分别为67％、15.6％和14.3％;胰腺癌组织中GST-π阳性率明显高于其它组织（P<0.05）。胰腺癌高分化组织中GST-π耐药基因表达也明显高于低分化组织（P<0.05）。GST-π耐药基因表达与胰腺癌病人的性别、年龄、肿瘤的部位、大小、侵袭性及临床分期等指标无关（P>0.05）,GST-π耐药基因表达阳性病人平均术后生存时间长于GST-π阴性病人。结论 GST-π可能参与胰腺癌的早期癌变过程,并在维护肿瘤的特性中起到一定的作用,GST-π耐药基因有可能成为胰腺癌的早期肿瘤酶标记物;GST-π耐药基因与胰腺癌的“天然性多药耐药”和肿瘤生物学特性有关,它是指导肿瘤化疗和预后的一个重要指标。
Objective To detect the expression of GST-π resistance gene in pancreatic cancer and its clinical significance. Methods S-P immunohistochemical method was used to detect the protein expression of GST-π resistance in 150 cases of abnormal and normal pancreatic tissue specimens (including 97 cases of primary pancreatic cancer, 32 cases of pancreatitis and 21 cases of normal pancreatic tissue). Results GST-π resistance gene in pancreatic cancer. The positive rates of pancreatic cancer and normal pancreatic tissue were 67%, 15.6% and 14.3% respectively. The positive rate of GST-π in pancreatic cancer tissues was significantly higher than that in other tissues (P <0.05). The expression of GST-πmRNA in well differentiated pancreatic cancer tissues was also significantly higher than that in poorly differentiated tissues (P <0.05). The expression of GST-π resistance gene was not related to the gender, age, tumor location, size, invasion and clinical stage of patients with pancreatic cancer (P> 0.05). The average postoperative survival time of patients with GST- Longer than GST-π negative patients. Conclusion GST-π may be involved in the early carcinogenesis of pancreatic cancer and play a role in the maintenance of tumor characteristics. GST-πmRNA may be an early tumor marker of pancreatic cancer; GST-πmRNA And pancreatic cancer “natural multidrug resistance” and tumor biological characteristics, it is to guide tumor chemotherapy and prognosis is an important indicator.